While the sobering reality is that lung cancer's overall five-year survival rate hovers around just 26%, a closer look at the statistics reveals a powerful and hopeful story of progress, pinpointing where modern medicine is winning the fight.
Key Takeaways
- The 5-year relative survival rate for all stages of lung and bronchus cancer combined in the US from 2014-2020 is 26.7%
- Overall 5-year survival rate for lung cancer patients diagnosed between 2013-2019 is 22.9% according to SEER data
- The median survival time for metastatic lung cancer patients is approximately 12 months
- The 5-year relative survival rate for localized lung cancer (all stages confined to primary site) is 63%
- For regional stage lung cancer (spread to regional lymph nodes), 5-year survival is 35%
- Distant metastatic lung cancer has a 5-year survival of 8.1%
- For non-small cell lung cancer (NSCLC), the 5-year survival rate is 28%
- Small cell lung cancer (SCLC) 5-year survival rate is 7%
- NSCLC adenocarcinoma 5-year survival is 27%
- Surgery for stage I NSCLC improves 5-year survival to 80-90%
- Chemotherapy alone for advanced NSCLC median survival 10 months
- Targeted therapy for EGFR-mutant NSCLC median OS 38 months
- 5-year survival for lung cancer in females is 28.2% vs 25.1% in males (SEER)
- Black Americans have 5-year lung cancer survival of 21.5% vs 27.6% whites
- Patients under 65 years have 33% 5-year survival vs 22% over 65
Lung cancer survival rates stay low but show steady gains into 2026.
Demographic and Risk Factor Survival
15-year survival for lung cancer in females is 28.2% vs 25.1% in males (SEER)
Verified2Black Americans have 5-year lung cancer survival of 21.5% vs 27.6% whites
Verified3Patients under 65 years have 33% 5-year survival vs 22% over 65
Verified4Never-smokers lung cancer 5-year survival 30% higher than smokers
Directional5Asian/Pacific Islander lung cancer 5-year survival 30.3%
Single source6Hispanic lung cancer patients 5-year survival 24.7%
Verified7Rural residents have 20% lower lung cancer survival than urban
Verified8Women with NSCLC have 5-year survival 32% vs 25% men
Verified9Elderly (>80) lung cancer 1-year survival 25%
Directional10Comorbid COPD reduces 5-year survival by 10-15%
Single source11Performance status 0-1 patients 5-year survival 35% vs 10% PS 2+
Verified12Low SES linked to 5-year survival 18% vs 25% high SES
Verified13Obese patients (BMI>30) 5-year survival 22% vs 26% normal
Verified14Former smokers survival better by 5% than current
Directional15Married patients 5-year survival 28% vs 22% unmarried
Single source16Diabetes comorbidity lowers median survival by 3 months
Verified17Heavy smokers (>40 pack-years) 5-year survival 18%
Verified18Young adults (<50) 5-year survival 35%
Verified19American Indian/Alaska Native 5-year survival 20.5%
Directional20Insured patients survival 27% vs 19% uninsured
Single source21EGFR mutations more common in women, improving survival to 45%
Verified22Smoking cessation pre-diagnosis increases 5-year survival by 15%
Verified23Cardiovascular disease comorbidity reduces OS by 20%
Verified24Urban vs rural survival gap 5-10% higher in cities
Directional255-year survival for localized NSCLC in women is 70%
Single sourceDemographic and Risk Factor Survival Interpretation
These survival statistics reveal that lung cancer is less a monolithic death sentence and more a biased accountant, coldly calculating your odds based on who you are, where you live, what you earn, and whether you quit smoking in time.
Histology-Specific Survival
1For non-small cell lung cancer (NSCLC), the 5-year survival rate is 28%
Verified2Small cell lung cancer (SCLC) 5-year survival rate is 7%
Verified3NSCLC adenocarcinoma 5-year survival is 27%
Verified4NSCLC squamous cell carcinoma 5-year survival is 24%
Directional5Large cell carcinoma 5-year survival is 17%
Single source6Limited-stage SCLC 5-year survival 27%
Verified7Extensive-stage SCLC 5-year survival 3%
Verified8Adenocarcinoma in never-smokers 5-year survival 40%
Verified9Squamous cell in smokers 5-year survival 20%
Directional10NSCLC with EGFR mutation 5-year survival 50% with targeted therapy
Single source11SCLC with prophylactic cranial irradiation improves 3-year survival to 20%
Verified12NSCLC large cell neuroendocrine 5-year survival 15-25%
Verified13Adenocarcinoma NOS 5-year survival 25%
Verified14In Asian populations, adenocarcinoma survival 35% at 5 years
Directional15SCLC oat cell subtype median survival 9 months
Single source16NSCLC bronchioalveolar carcinoma 5-year survival up to 80% early stage
Verified17Mixed histology NSCLC 5-year survival 22%
Verified18SCLC combined small cell 5-year survival 10%
Verified19EGFR-positive adenocarcinoma median PFS 18 months
Directional20ALK-rearranged NSCLC 5-year survival 60% with inhibitors
Single source21ROS1 fusion NSCLC OS 5 years 40-50%
Verified22Squamous NSCLC PD-L1 high 2-year survival 50% with IO
VerifiedHistology-Specific Survival Interpretation
In this grim statistical arena, the cold numbers tell a clear and brutal story: while your specific battlefield—be it a mutation, a stage, a histology, or a treatment—absolutely matters, lung cancer, on the whole, remains a formidable and often ruthless opponent.
Overall Survival Rates
1The 5-year relative survival rate for all stages of lung and bronchus cancer combined in the US from 2014-2020 is 26.7%
Verified2Overall 5-year survival rate for lung cancer patients diagnosed between 2013-2019 is 22.9% according to SEER data
Verified3The median survival time for metastatic lung cancer patients is approximately 12 months
Verified41-year survival rate for lung cancer in England (2016-2020) is 38%
Directional5Global 5-year survival rate for lung cancer is around 19% based on CONCORD-3 study
Single source6In Japan, the 5-year survival rate for lung cancer improved to 33% from 2006-2008 data
Verified7US lung cancer 5-year survival rate increased from 12% in 1975 to 26% in 2020
Verified8For never-smokers with lung cancer, 5-year survival is 30.8% vs 21.3% for smokers
Verified9Age-standardized 5-year net survival for lung cancer in Europe averages 15-20%
Directional10In Canada, 5-year survival for lung cancer is 19% (2014-2018)
Single source11Australian lung cancer 5-year survival rate is 21% (2014-2018)
Verified12UK lung cancer 1-year survival rose to 42% by 2016-2020
Verified13Median overall survival for advanced lung cancer is 11.6 months in real-world data
Verified143-year survival rate for lung cancer in the US is 35%
Directional15In China, 5-year survival for lung cancer is 16.8% (urban areas)
Single source16SEER data shows 10-year survival for lung cancer at 6.3%
Verified17Survival at 5 years for lung cancer patients over 65 is 20.1%
Verified18Global trends show lung cancer survival improving by 1-2% per decade
Verified19In France, 5-year survival for lung cancer is 17%
Directional20US non-Hispanic white lung cancer 5-year survival is 27.1%
Single source21Overall 5-year survival rate for lung cancer diagnosed 2014-2020 is 26.7% per SEER
Verified221-year survival for all lung cancer stages in US is 56%
Verified23Median survival for untreated lung cancer is 4-6 months
Verified245-year survival in high-income countries averages 20%
Directional25Korean lung cancer 5-year survival 34.1% (2010-2014)
Single source26Survival improvement 3% per year in targeted therapy era
Verified2710-year lung cancer survivor rate 6.9%
Verified28In Germany, 5-year survival 21%
Verified29Italian lung cancer 5-year net survival 17%
DirectionalOverall Survival Rates Interpretation
While these numbers are still sobering, they whisper the cautious, hard-won progress of modern medicine: a patient diagnosed with lung cancer today is more than twice as likely to be alive in five years than they would have been fifty years ago, yet the overall odds remain a grim roll of the dice.
Stage-Based Survival
1The 5-year relative survival rate for localized lung cancer (all stages confined to primary site) is 63%
Verified2For regional stage lung cancer (spread to regional lymph nodes), 5-year survival is 35%
Verified3Distant metastatic lung cancer has a 5-year survival of 8.1%
Verified4Stage I NSCLC 5-year survival rate is 68-92% depending on substage
Directional5Stage II NSCLC 5-year survival is 53-60%
Single source6Stage IIIA NSCLC 5-year survival is 36%
Verified7Stage IIIB NSCLC 5-year survival drops to 26%
Verified8Stage IV NSCLC 5-year survival is 9%
Verified9For limited-stage SCLC, 5-year survival is 29%
Directional10Extensive-stage SCLC 5-year survival is 3%
Single source11Stage IA lung cancer 5-year survival exceeds 90%
Verified12Stage IB NSCLC 5-year OS is 68%
Verified13Stage IIA 5-year survival for NSCLC is 60%
Verified14Stage IIB NSCLC 5-year survival is 53%
Directional15Stage IIIA 5-year survival in NSCLC is 24-36%
Single source16Stage IIIB 5-year survival 13-25% in NSCLC
Verified17Stage IV NSCLC median survival 11 months by stage
Verified18Localized lung cancer 5-year survival 61% (2014-2020 SEER)
Verified19Regional lung cancer 5-year survival 34% (SEER 2014-2020)
Directional20In stage I SCLC, 5-year survival is up to 50% with treatment
Single source21Stage IV lung cancer 1-year survival is 32%
Verified22Early-stage (I-II) NSCLC surgery alone 5-year survival 70-90%
Verified23Advanced stage (III-IV) lung cancer 2-year survival 25%
Verified245-year survival for NSCLC is 28% overall, with stage I at 92%
Directional25SCLC limited stage median survival 15-20 months
Single source26NSCLC adenocarcinoma stage I 5-year survival 83%
Verified27Squamous cell stage II 5-year survival 65%
Verified28Stage 0 lung cancer (carcinoma in situ) 5-year survival 100%
Verified29Unknown stage lung cancer 5-year survival 11%
Directional30Stage I squamous cell 5-year survival 80%
Single source31Stage III SCLC 5-year survival <5%
Verified32Distant stage adenocarcinoma 5-year survival 7%
Verified33Regional SCLC 5-year survival 18%
VerifiedStage-Based Survival Interpretation
The numbers tell a brutally simple story: where lung cancer is found defines your fate, with survival rates plummeting from a hopeful whisper in the early stages to a grim statistic once it has marched beyond its original borders.
Treatment-Related Survival
1Surgery for stage I NSCLC improves 5-year survival to 80-90%
Verified2Chemotherapy alone for advanced NSCLC median survival 10 months
Verified3Targeted therapy for EGFR-mutant NSCLC median OS 38 months
Verified4Immunotherapy (pembrolizumab) for PD-L1+ NSCLC 5-year OS 20%
Directional5Stereotactic body radiotherapy (SBRT) for early-stage NSCLC 5-year survival 85-90%
Single source6Concurrent chemoradiation for stage III NSCLC 5-year survival 30%
Verified7Limited-stage SCLC with chemo+RT 5-year survival 25-30%
Verified8Osimertinib in EGFR T790M NSCLC median OS 38.6 months
Verified9Alectinib for ALK+ NSCLC 5-year OS 63%
Directional10Nivolumab for squamous NSCLC 2-year OS 29%
Single source11Lobectomy vs wedge resection stage I NSCLC 5-year survival 88% vs 82%
Verified12Adjuvant chemotherapy post-surgery stage II NSCLC improves 5-year survival by 5%
Verified13Proton therapy for stage III NSCLC 3-year survival 50%
Verified14Durvalumab consolidation after chemoradiation stage III NSCLC 5-year OS 43%
Directional15Carboplatin-paclitaxel chemo median survival 8-10 months stage IV
Single source16Crizotinib for ROS1 NSCLC median PFS 19.2 months
Verified17PCI in limited SCLC increases 3-year survival from 15% to 21%
Verified18Neoadjuvant chemo for resectable NSCLC 3-year survival 65%
Verified19IO + chemo first-line stage IV NSCLC 2-year survival 50%
Directional20Lorlatinib for ALK NSCLC 5-year OS 60%
Single sourceTreatment-Related Survival Interpretation
The progress in lung cancer survival is a stark tale of two realities: a near-cure for early stages and a hard-fought, incremental gain for advanced disease, where each new therapy is a crucial foothold on a steeper cliff.
Sources & References
- Reference 1SEERseer.cancer.govVisit source
- Reference 2CANCERcancer.orgVisit source
- Reference 3CANCERRESEARCHUKcancerresearchuk.orgVisit source
- Reference 4PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 5CANCERcancer.govVisit source
- Reference 6CANCERcancer.caVisit source
- Reference 7AIHWaihw.gov.auVisit source